- Reference #:
- FEI 3006731547
- Product:
- Drugs
- Recipient:
-
Recipient Name
Mr. Young-Gi Son
-
Recipient Title
President
- Natuzen Co., Ltd.
289 Namdongdong-Ro
Namdong-gu
Incheon
21639
South Korea
- Issuing Office:
- Center for Drug Evaluation and Research (CDER)
United States
Secondary Issuing Offices
Dear Mr. Son:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-24-36 dated May 3, 2024.
Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Joel Hustedt
Compliance Officer
Division of Drug Quality II
